Tandem Diabetes Care, Inc. Earnings Recaps
Q3 2025
Nov 7, 2025
Tandem Diabetes Care reported record Q3 sales, driven by significant advancements in commercial operations and successful product launches, positioning the company for future growth.
Key takeaways
- Record Q3 sales driven by improved sales productivity and an effective commercial transformation in the U.S.
- Successful launch of t:slim X2 with Abbott's FreeStyle Libre 3 Plus integration, enhancing user access to advanced diabetes management technology.
- Expansion of Type 2 diabetes efforts showing promising results, doubling the company's addressable market in the U.S.
- Direct sales initiatives in Europe slated to begin in early 2026, enhancing growth potential and margin expansion.
- Increased pharmacy benefit coverage for Tandem Mobi reaching over 40% of U.S. lives, marking a significant milestone in revenue generation.